孙海滨 包华

[摘要] 目的 探讨双抗治疗进展性脑卒中的效果。 方法 回顾性分析2014年5月至2019年5月呼伦贝尔市人民医院神经内科住院治疗的进展性脑卒中患者300例。给予双抗治疗的进展性卒中患者150例为观察组，给予单抗治疗的进展性卒中患者150例为对照组。通过上述治疗后，观察两组NIHSS评分、mRs评分、临床疗效及并发症发生率。 结果 观察组患者入院14 d NIHSS评分及mRs评分均较对照组明显下降，差异有统计学意义（t=24.225、22.364，P<0.05）。 结论 对于进展性卒中，双抗治疗优于单抗治疗。

[关键词] 进展性脑卒中;单抗治疗;双抗治疗;美国国立卫生研究院卒中量表;改良Rankin评分量表

[中图分类号] R453          [文献标识码] B          [文章编号] 1673-9701（2021）36-0057-03

Effect of double-antibody therapy on progressive stroke

SUN Haibin   BAO Hua

Department of Neurology， Hulunbeier People′s Hospital in Inner Mongolia Autonomous Region， Hulunbeier   021008， China

[Abstract] Objective To explore the effect of double-antibody therapy in the treatment of progressive stroke. Methods A total of 300 patients with progressive stroke hospitalized in the Department of Neurology， Hulunbeier People′s Hospital from May 2014 to May 2019 were retrospectively analyzed.150 patients with progressive stroke were treated with double-antibody as the observation group， and 150 patients with progressive stroke were treated with monoclonal antibody as the control group.After the above treatment， NIHSS score and mRs score， clinical efficacy and complication rate were observed. Results Compared with the control group， the NIHSS score and mRs score in the observation group of 14 d of admission were significantly lower than those in the control group，and the differences were statistically significant（t=24.225， 22.364， P<0.05）. Conclusion Double-antibody therapy is superior to monoclonal antibody therapy for progressive stroke.

[Key words] Progressive stroke; Monoclonal antibody therapy; Double-antibody therapy; National institutes of health stroke scale; Modified rankin scale

腦卒中具有发病率高、复发率高、致残率高和死亡率高等特点。在全球范围内，脑卒中已成为人类死亡的第二大病因和成人致残的主要原因。中国是最大的发展中国家，人口占世界总人口的1/5，其脑卒中现患病人数高居世界首位，也是我国居民死亡的首位病因。脑卒中分为缺血性卒中及出血性卒中，以缺血性卒中为主，而脑血栓形成为常见类型。按病因及发病机制等分型分类众多，其中较为严重的类型有进展性卒中、前后循环大面积脑梗死等，皆可造成严重后果，甚至危及生命，故本篇文章着重讨论进展性卒中的相关治疗。

进展性脑卒中是严重危及患者生命、影响临床预后的一类脑卒中，是脑梗死死亡率增高的主要原因之一。在临床工作中，往往因对该类疾病的认识不足，容易导致诊断及治疗的延迟。……